SCGC Acquisition and Expansion Strategy

Q4/22 Consolidated Results 142,666 Revenues from Sales 142,391 -14% y-o-y -14% q-o-q 122,190 Q4/21 Q3/22 Q4/22 21,410 4,267 EBITDA EBITDA -53% y-o-y +9% 9-0-9 8,307 P.57 Profit for the Period -98% y-o-y -94% q-o-q 2,444 157 Q4/21 Q3/22 Q4/22 Equity Income -17% y-o-y -9% q-o-q 9,322 200 10,122 17,143 4,118 Dividend from Associates 2,248 2,064 1,871 823 Chemicals 9,122 EBITDA from 1,715 1,108 6,004 Operations 1,241 Non-Chemicals 533 763 Q4/21 Q3/22 Q4/22 Q4/21 Q3/22 Q4/22 SCG

View entire presentation